UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 5, 2014
 

GLOBUS MEDICAL, INC.
(Exact name of registrant as specified in charter)
 

 
 
 
 
 
 
DELAWARE
 
001-35621
 
04-3744954
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403
(Address of principal executive offices) (Zip Code)
(610) 930-1800
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 








Item 5.07. Submission of Matters to a Vote of Security Holders.
The Annual Meeting of Stockholders (the “Annual Meeting”) of Globus Medical, Inc. (the “Company”) was held on June 5, 2014. At the Annual Meeting, the stockholders voted on the following three proposals and cast their votes as described below.
Proposal 1
The individuals listed below were each elected at the Annual Meeting to serve a three-year term on the Company's Board of Directors.
Nominee
For
Against
Abstain
Broker Non-Vote
David M. Demski
288,019,048
26,967,921
211,702
13,040,969
Kurt C. Wheeler
313,663,567
1,322,102
213,002
13,040,969
Proposal 2
A proposal to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2014, as described in the Company’s definitive proxy statement on Schedule 14A (the “Proxy Statement”) filed with the Securities and Exchange Commission. This proposal was approved.
For
Against
Abstain
Broker Non-Vote
327,176,072
839,852
223,716
Proposal 3
A non-binding advisory vote to approve the compensation of the Company's named executive officers, as described in the Proxy Statement. This proposal was approved.
For
Against
Abstain
Broker Non-Vote
310,323,818
4,631,655
243,198
13,040,969







SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
 
GLOBUS MEDICAL, INC.
 
 
(Registrant)
 
 
 
Dated:
June 11, 2014
/s/ ANTHONY L. WILLIAMS
 
 
 
 
 
Anthony L. Williams
 
 
Senior Vice President of Business Development & General Counsel